Lisata Therapeutics reports 2024 net loss $20M, cash $31.2M; promising Phase 2b pancreatic cancer data

LISATA THERAPEUTICS, INC.

2024-FY EPS reported -$2.40 vs consensus -$0.78 ▼ miss (-209.6%)

Revenue $1.0M from Kuva license (vs $0 in 2023); operating expenses down 8.9% to $23.4M.
Net loss $20.0M vs $20.8M in 2023; cash, equivalents & securities $31.2M; runway into Q2 2026.
Phase 2b ASCEND (mPDAC) showed positive OS trend; four complete responses in certepetide arm, none in placebo.
BOLSTER (cholangiocarcinoma) first-line enrollment complete; topline data expected mid-2025.
iLSTA (PDAC+immunotherapy) 27 of 30 enrolled; enrollment completion H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.